Sotorasib in KRAS(G12C) mutated lung cancer: Can we rule out cracking KRAS led to worse overall survival?

The KRAS oncogene is present in up to 25% of solid tumors and for decades had been undruggable. Sotorasib was the first-in-class KRAS inhibitor to reach the US and European market, and its pharmacological inhibition is restricted to the KRAS p.G12C mutation. Sotorasib showed activity (tumor shrinkag...

Descripción completa

Detalles Bibliográficos
Autores principales: Olivier, Timothée, Haslam, Alyson, Prasad, Vinay
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2022
Materias:
Perspective
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9803768/
https://www.ncbi.nlm.nih.gov/pubmed/36577165
http://dx.doi.org/10.1016/j.tranon.2022.101591

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9803768/
https://www.ncbi.nlm.nih.gov/pubmed/36577165
http://dx.doi.org/10.1016/j.tranon.2022.101591

Ejemplares similares